How Much Can I Do in My Practice to Address Obesity?
During this webinar. Dr. Eckel, Dr. Kushner, and Dr. Wyatt discuss practical approaches for the management of obesity in T2DM by utilizing a complex patient case. They engage in meaningful discussions and offer several pearls about how to prioritize your options and come up with tangible goals to address during a visit, in collaboration with the patient and the extended healthcare team.
- Challenges with addressing obesity in the primary care setting
- Practical points – what can be addressed in a standard healthcare visit
- Multidisciplinary collaboration
- How to set individualize and realistic short-and long-term treatment goals in collaboration with the patient
Primary care physicians, cardiologists, endocrinologists, nurses, nurse practitioners, physician assistants, and pharmacists.
After completing this activity, the participant should be better able to:
- Review strategies that foster shared decision-making and practical approaches for addressing obesity in patients with type 2 diabetes
- Develop individualized treatment options that address the treatment of obesity in patients with type 2 diabetes based on available options, recommendations, and patient preferences
Robert H. Eckel, MD (Chair/Moderator)
Professor of Medicine, Emeritus
University of Colorado Anschutz Medical Campus<
Dr. Eckel has nothing to disclose.
Robert Kushner, MD, MS, FACP (Faculty)
Professor, Departments of Medicine and Medical Education
Northwestern University Feinberg School of Medicine
Director, Center for Lifestyle Medicine
Dr. Kushner discloses the following:
Consultant/Advisory Board: Novo Nordisk, WW, Lilly, Pfizer
Holly R. Wyatt MD (Faculty)
Professor and Vice Chair of Clinical Programs
Department of Nutrition Sciences
School of Health Professions
University of Alabama Birmingham
Dr. Wyatt discloses the following:
Employee/Owner: Shakabuku LLC- ownership interest and manager
Dr Holly LLC- ownership interest and manager
Grant/Research Support: Novo Nordisk- grant; Gelesis- grant; Epitomee- grant; National Cattleman's Beef association- grant
Speakers Bureau/Honoraria for non-CME: Novo Nordisk- speaking fee
Consultant/Advisory Board: Gelesis- consulting fee
Non-Mutual funds Stock Ownership/Stock options: Roman Health- future stock options <5%
Patent Holder/ Royalties paid to you: Energy Gap- patent; Rodale publisher of Book - royalties
Other financial or material support: IP owned by Shakabuku LLC; IP licensed to University of Colorado
ESTIMATED TIME TO COMPLETE ACTIVITY
EDUCATIONAL GRANT SUPPORT
This activity is supported by educational grant provided by Lilly USA, LLC.
JOINT ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Cardiometabolic Health Congress (CMHC). Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CONTINUING MEDICAL EDUCATION
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hours.
CONTINUING PHARMACY EDUCATION
Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour(s) (.10 CEUs) of the Accreditation Council for Pharmacy Education.
This is a knowledge-based activity. Universal Activity Numbers (UAN): JA4008162-9999-22-380-H01-P
For Pharmacists: Upon completing the post-test and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 – 6 weeks.
DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The PIM planners and others have nothing to disclose. The CMHC planners and others have nothing to disclose.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
METHOD OF PARTICIPATION & REQUEST FOR CREDIT
During the period November 15, 2022 through November 14, 2023, participants must read the learning objectives and faculty disclosures, study the educational activity, obtain a score of 75% or better on the post-test, and complete the evaluation. Upon completing, your certificate will be available for print. For questions about receiving certificates, please contact us at CMHC_Eval@cardiometabolichealth.org.
For questions about the accreditation of this activity, please visit www.pimed.com.
For Pharmacists: Please complete the evaluation instructions above. Upon registering and completing the activity evaluation, your transcript information will be sent to the NABP CPE Monitor Service within 4-6 weeks.
- 1.00 ACPE Pharmacy
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 Participation
A computer with an internet connection
Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
Other additional software may be required such as PowerPoint or Adobe Acrobat Reader.